Aerocrine AB has announced that the company has entered into a distribution agreement with Chest M.I. Inc. to market and sell NIOX MINO, capable of enabling the fast and reliable management of airway inflammation and effective in the diagnosis, treatment and follow-up of asthma patients, throughout Japan.

Chest manufactures and sells a large range of products to measure lung function as well oxygen delivery systems for home use, and is one of the largest companies in its field with over 50% share of the Japanese market.

Chest will apply for market authorization of Aerocrine’s NIOX MINO in Japan and then proceed to product launch.

“Chest is an ideal partner for marketing and sales of our product in Japan,” said Paul de Potocki, CEO of Aerocrine.

“The company has established relations and years of experience from selling medical devices to our prime target groups. Chest has also shown an impressive knowledge and enthusiasm for our product and method of inflammatory control,” he said.

Up to 8 million people suffers from asthma in Japan and the disease causes around 3,000 deaths per year, primarily due to inferior disease control. NIOX MINO is a handheld device that in just a couple of minutes gauges the inflammation in the airways, the underlying cause of asthma and the treatment of asthma focuses primarily on keeping such inflammation under control.

Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK.